Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Not Yet Opened 02-27 16:00:00 EST

0.9167

+0.0366

+4.16%

盘后0.8650

-0.0517-5.64%

19:48 EST

High0.9167	Low0.8200	Vol110.42K
Open0.8625	D1 Closing0.8801	Amplitude10.99%
Mkt Cap6.41M	Tradable Cap4.18M	Total Shares6.99M
T/O98.35K	T/O Rate2.42%	Tradable Shares4.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.9167,"timestamp":1772226000000,"preClose":0.8801,"halted":0,"volume":110420,"hourTrading":{"tag":"盘后","latestPrice":0.865,"preClose":0.9167,"latestTime":"19:48 EST","volume":1970,"amount":1734.3127,"timestamp":1772239737711,"change":-0.0517,"changeRate":-0.056398,"amplitude":0.053016},"delay":0,"changeRate":0.0415861833882513,"floatShares":4561818,"shares":6993838,"eps":-2.136425,"marketStatus":"Not Yet Opened","change":0.0366,"latestTime":"02-27 16:00:00 EST","open":0.8625,"high":0.9167,"low":0.82,"amount":98348.91320499999,"amplitude":0.109874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.136425,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":0,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.8801,"postHourTrading":{"tag":"盘后","latestPrice":0.865,"preClose":0.9167,"latestTime":"19:48 EST","volume":1970,"amount":1734.3127,"timestamp":1772239737711,"change":-0.0517,"changeRate":-0.056398,"amplitude":0.053016},"volumeRatio":0.6777297547432712,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE/wiki","defaultTab":"wiki","newsList":[{"id":"2612269384","title":"Aprea Therapeutics files to sell 12.58M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2612269384","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612269384?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:11","pubTimestamp":1771585880,"startTime":"0","endTime":"0","summary":"06:08 EST Aprea Therapeutics (APRE) files to sell 12.58M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-files-to-sell-12-58m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-files-to-sell-12-58m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","APRE","BK4007"],"gpt_icon":0},{"id":"2612494344","title":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2612494344","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612494344?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:06","pubTimestamp":1771423609,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051Feb 18 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2612463964","title":"Aprea Therapeutics announces additional clinical activity for APR-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463964","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612463964?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:17","pubTimestamp":1771420633,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (APRE) announced additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-additional-clinical-activity-for-apr-1051-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-additional-clinical-activity-for-apr-1051-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE","LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2612445164","title":"Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445164","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445164?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:02","pubTimestamp":1771419721,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses  and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8bnrb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4585","LU2095319765.USD","APRE","BK4588","BK4139","NDAQ"],"gpt_icon":0},{"id":"2612917445","title":"Aprea Therapeutics Inc - Update From Trial Is Expected in Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612917445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612917445?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419608,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2612445692","title":"Aprea Therapeutics Inc - Tumor Shrinkage of 50% and Significant CA-125 Biomarker Reduction Observed at 220 Mg Dose Level","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445692?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419608,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2612445630","title":"Aprea Therapeutics Announces Additional Positive Clinical Activity for Wee1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing Acesot-1051 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445630","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445630?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2610192475","title":"BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192475?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:02","pubTimestamp":1770904933,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer TherapeuticsFeb 12 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS STRENGTHENS GLOBAL PATE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8RDH3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2610921439","title":"Aprea Therapeutics Inc - Existing Issued Patents Expected to Remain in Force Through 2035-2037","url":"https://stock-news.laohu8.com/highlight/detail?id=2610921439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610921439?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8RDH3K:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2610907921","title":"Aprea Therapeutics Inc - Granted New Patents in Australia and Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610907921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610907921?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8RDH3K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2610219049","title":"Aprea Therapeutics Inc -  Core Patent Families Expected to Provide Exclusivity Into 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2610219049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610219049?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8RDH3K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2610712996","title":"Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2610712996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610712996?lang=en_us&edition=fundamental","pubTime":"2026-02-12 10:14","pubTimestamp":1770862480,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response  oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8z4Rw5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2610996017","title":"Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (Ddr) Cancer Therapeutics, Paving Way for Pipeline Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2610996017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610996017?lang=en_us&edition=fundamental","pubTime":"2026-02-12 10:14","pubTimestamp":1770862468,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUC8L21VX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2608362990","title":"Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362990","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608362990?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:30","pubTimestamp":1770211809,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. has appointed Eugene Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy brings over 20 years of experience in oncology drug development and will support the company as it advances clinical development of its WEE1 inhibitor, APR-1051, for advanced solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL9jjCT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","APRE","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2608890525","title":"Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608890525","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608890525?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:08","pubTimestamp":1770066513,"startTime":"0","endTime":"0","summary":"Gilad Oren, President and CEO of Aprea Therapeutics Inc., reported the acquisition of common shares of Aprea Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6KPFfc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2608890582","title":"Aprea Therapeutics CFO John P. Hamill Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608890582","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608890582?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:06","pubTimestamp":1770066376,"startTime":"0","endTime":"0","summary":"John P. Hamill, Senior Vice President, Chief Financial Officer, and Principal Financial and Accounting Officer of Aprea Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6pmXFl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFG","BK4162","LU1989772923.USD","BK4588","BK4585","BK4139","BK4534","APRE","LU1989772840.SGD","BK4566"],"gpt_icon":0},{"id":"2607040082","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:52 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040082","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040082?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:52","pubTimestamp":1769791939,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:52 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nAQN2LK3ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2607354038","title":"Aprea Therapeutics prices 6.29M shares at 89c in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2607354038","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607354038?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:37","pubTimestamp":1769693829,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (APRE) entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-prices-6-29m-shares-at-89c-in-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-prices-6-29m-shares-at-89c-in-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE","BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2607038800","title":"Aprea Therapeutics announces early PoC data in ACESOT-1051 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2607038800","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607038800?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:36","pubTimestamp":1769693807,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (APRE) announced the first unconfirmed partial response observed in a patient enrolled in its ongoing Phase 1 ACESOT-1051 dose-e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-early-poc-data-in-acesot-1051-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-early-poc-data-in-acesot-1051-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2607908094","title":"Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607908094","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607908094?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:27","pubTimestamp":1769693229,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. announced early clinical proof-of-concept results from its ongoing Phase 1 ACESOT-1051 dose-escalation trial evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. Preliminary data include the observation of an unconfirmed partial response in a patient with endometrial cancer at the 150 mg dose, with approximately 50% reduction in target lesion size and greater than 90% decrease in CA-125 levels. The study is currently enrolling patients in the 220 mg cohort, with a potential dose-response trend observed across the 70 mg, 100 mg, and 150 mg groups. Additional study updates are expected in the first half of 2026, and dose escalation is anticipated to be completed later in the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL3LQq0M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","APRE","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":0.2097},{"period":"1month","weight":0.1997},{"period":"3month","weight":-0.2725},{"period":"6month","weight":-0.4142},{"period":"1year","weight":-0.6333},{"period":"ytd","weight":0.0747}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.101733},{"month":4,"riseRate":0,"avgChangeRate":-0.145433},{"month":5,"riseRate":0,"avgChangeRate":-0.129229},{"month":6,"riseRate":0.333333,"avgChangeRate":0.023066},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.044399},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005221},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction